Posted in | News | Light / Image Sensor

PositiveID’s Subsidiary Submits New Government Contract

Positive ID (PSID), a company that develops medical technologies for bio-threat detection, clinical diagnostics and diabetes management, has declared that its subsidiary, MicroFluidic Systems (MFSI), has both qualified and tendered a new government proposal, which would take the company’s entire pipeline of new government contracts to more than $37 million.

Most of the contracts that MFSI is planning to submit or has already submitted would be awarded in the year 2011. The latest proposal is for a cartridge based radiation dosimeter, which is built on the basis of MFSI’s Dragonfly technology.

MFSI was created in 2001 and specializes in producing automated instruments for a broad range of applications used to detect and process biological samples. So far, MFSI has been awarded more than $45 million in government contracts, most of which have come from the Department of Homeland Security and a few from the Department of Defense and the Health and Human Services.

The Microfluidics-based Bioagent Autonomous Networked Detector (M-Band) and the Dragonfly are the two major products of MFSI. The Dragonfly includes small microfluidic cartridges for detection and biological sample processing, and also clinical sample detection and processing of samples such as antibiotic-resistant bacteria, human papilloma virus, forensic applications, bio threat agents and environmental bacteria such as E.coli. The M-Band pathogen detection system is an ultra-sensitive bio aerosol monitor, which is completely autonomous and is capable of acting as an early warning system against biological attacks, while analyzing air samples non-stop for detecting bacteria, toxins and viruses and giving the results in just two hours.

According to Scott R Silverman, CEO and Chairman of PositiveID, MFSI”s pipeline and technologies are of high quality, which was the main reason for them to acquire MFSI. He further stated that their proven record of winning government contracts along with a wide range of commercial applications would prove to be beneficial for PositiveID both from a financial and an operational angle.



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Choi, Andy. (2019, February 24). PositiveID’s Subsidiary Submits New Government Contract. AZoSensors. Retrieved on February 27, 2024 from

  • MLA

    Choi, Andy. "PositiveID’s Subsidiary Submits New Government Contract". AZoSensors. 27 February 2024. <>.

  • Chicago

    Choi, Andy. "PositiveID’s Subsidiary Submits New Government Contract". AZoSensors. (accessed February 27, 2024).

  • Harvard

    Choi, Andy. 2019. PositiveID’s Subsidiary Submits New Government Contract. AZoSensors, viewed 27 February 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Azthena logo powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Azthena logo with the word Azthena

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.